Insulin producing cells derived from pluripotent stem cells
First Claim
1. A method of generating human islet cells or human islet progenitor cells from human pluripotent stem cells and selecting for insulin producing cells, the method comprising:
- (a) culturing the human pluripotent stem cells for a period ranging from 5 to 8 days in a differentiation medium comprising glucose so as to differentiate the human pluripotent stem cells into endoderm cells expressing Sox17 and FoxA2;
(b) after obtaining said endoderm cells, culturing said endoderm cells for a period ranging from 2 to 10 days in a medium comprising forskolin, retinoic acid, glucose and at least one growth factor, the least one growth factor selected from the group consisting of FGF10,bFGF and FGF7 so as to generate PDX-1 positive cells;
(c) culturing said PDX-1 positive cells in a medium comprising glucose and at least one maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells or islet progenitor cells from pluripotent stem cells;
wherein the generating of human islet cells or human islet progenitor cells is effected without the generating of embryoid bodies;
(d) dispersing said islet cells or islet progenitor cells to generate dispersed human islet cells or dispersed human islet progenitor cells;
(e) contacting said islet cells or islet progenitor cells with an agent that binds to EpCAM;
(f) selecting cells which bind to said agent;
thereby generating human islet cells or human islet progenitor cells that produce insulin; and
(g) reaggregating said dispersed human islet cells or dispersed human islet progenitor cells that produce insulin.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.
-
Citations
19 Claims
-
1. A method of generating human islet cells or human islet progenitor cells from human pluripotent stem cells and selecting for insulin producing cells, the method comprising:
-
(a) culturing the human pluripotent stem cells for a period ranging from 5 to 8 days in a differentiation medium comprising glucose so as to differentiate the human pluripotent stem cells into endoderm cells expressing Sox17 and FoxA2; (b) after obtaining said endoderm cells, culturing said endoderm cells for a period ranging from 2 to 10 days in a medium comprising forskolin, retinoic acid, glucose and at least one growth factor, the least one growth factor selected from the group consisting of FGF10,bFGF and FGF7 so as to generate PDX-1 positive cells; (c) culturing said PDX-1 positive cells in a medium comprising glucose and at least one maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells or islet progenitor cells from pluripotent stem cells;
wherein the generating of human islet cells or human islet progenitor cells is effected without the generating of embryoid bodies;(d) dispersing said islet cells or islet progenitor cells to generate dispersed human islet cells or dispersed human islet progenitor cells; (e) contacting said islet cells or islet progenitor cells with an agent that binds to EpCAM; (f) selecting cells which bind to said agent; thereby generating human islet cells or human islet progenitor cells that produce insulin; and (g) reaggregating said dispersed human islet cells or dispersed human islet progenitor cells that produce insulin. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
Specification